Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer—A New York Cancer Consortium study (#N01-CM62204).
Stein S, Hochster H, Muggia F, Blank S, Curtin J, Shapira I, Goldberg G, Tiersten A. Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer—A New York Cancer Consortium study (#N01-CM62204). Journal Of Clinical Oncology 2010, 28: 5092-5092. DOI: 10.1200/jco.2010.28.15_suppl.5092.Peer-Reviewed Original ResearchOngoing phase II studyContinuous infusion topotecanPhase II studyRecurrent ovarian cancerII studyOvarian cancerConsortium studyCancerTopotecan